
|Articles|April 14, 2020
Glaucoma 360: New developments in pharma (Ellie Chabi, MD; Santen, Inc)
Author(s)Alex Delaney-Gesing
Advertisement
Ellie Chabi, MD, therapeutic area head for Glaucoma & Neuroprotection, lead for Artificial Intelligence Programs within Global Biomedical Science for Santen, shares insight on the company's role in the panel discussion focusing on new developments and discoveries in the glaucoma space during the 2020 Glaucoma 360 annual meeting in San Francisco, California.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approvals in 2025: What changed and why it matters for ophthalmologists
2
Achieving a new level of refractive precision: Surgical strategies
3
What changed in glaucoma care in 2025: Surgeon perspective
4
Global trial equity: How LMIC data is reshaping US ophthalmology research
5




